English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The SARS-CoV-2 viral pandemic is creating surges of COVID-19 hospitalizations and excess mortality. Watchful waiting and late-stage hospitalization have failed to resolve the crisis due to the complex and multifaceted pathophysiology of COVID-19 illness including viral mediated organ damage, cytokine storm, and thrombosis. Patients endure long untreated periods before succumbing to hospitalization and delayed treatment. Thus, early innovative, sequenced multidrug regimens have the best chance of success and are prudent as the next direction in randomized trials and advanced practice. Early management includes: 1) nutraceuticals, 2) combination anti-infective therapy, 3) corticosteroids, 4) antiplatelet agents/antithrombotics, 5) supportive care including supplemental oxygen, monitoring, and telemedicine. An immediate pivot from therapeutic nihilism to innovative sequenced multidrug regimens is required as the only strategy to reduce hospitalization and death in current acute cases of COVID-19.

Innovative Early Sequenced Multidrug Therapy for Sars-Cov-2 (Covid-19) Infection to Reduce Hospitalization and Death